TARGET- TARgeted Gene therapy for Epilepsy Treatment
TARGET- TARgeted Gene therapy for Epilepsy Treatment
Disciplines
Biology (15%); Computer Sciences (15%); Medical-Theoretical Sciences, Pharmacy (10%); Medical Biotechnology (60%)
Keywords
-
Gene Therapy,
Epilepsy,
Designer Receptor,
Neuroscience
More than 2 million patients suffer from treatment resistant epilepsy in Europe. Patients continue to experience seizures, suffer from several comorbidities, and have an increased risk of sudden unexpected death. Gene therapy, where proteins can be selectively overexpressed in different cell types, has emerged as a big hope for patients suffering from refractory epilepsy. In TARGET we will use state-of-the art computational methods, in vitro and in vivo electrophysiology, and behavioural experiments in order to develop and validate a novel gene therapy with an increased efficacy and safety profile.
- Christoph Schwarzer, Medizinische Universität Innsbruck , national collaboration partner
- Teresa Kaserer, Universität Innsbruck , associated research partner
Research Output
- 13 Citations
- 6 Publications
- 2 Disseminations
-
2025
Title Selective inhibition of NOX2 after status epilepticus attenuates epileptogenesis and cognitive impairment: A sex-dependent study DOI 10.1016/j.redox.2025.103830 Type Journal Article Author Singh K Journal Redox Biology Pages 103830 Link Publication -
2023
Title Dimethyl sulfoxide’s impact on epileptiform activity in a mouse model of chronic temporal lobe epilepsy DOI 10.1016/j.eplepsyres.2023.107235 Type Journal Article Author Widmann M Journal Epilepsy Research Pages 107235 Link Publication -
2023
Title Disruptor: Computational identification of oncogenic mutants disrupting protein-protein and protein-DNA interactions DOI 10.1038/s42003-023-05089-2 Type Journal Article Author Kugler V Journal Communications Biology Pages 720 Link Publication -
2024
Title Characterization of the intrahippocampal kainic acid model in female mice with a special focus on seizure suppression by antiseizure medications DOI 10.1016/j.expneurol.2024.114749 Type Journal Article Author Widmann M Journal Experimental Neurology Pages 114749 Link Publication -
2022
Title DISRUPTOR: Computational identification of oncogenic mutants disrupting protein interactions DOI 10.1101/2022.11.02.514903 Type Preprint Author Kugler V Pages 2022.11.02.514903 Link Publication -
2024
Title Disease-Associated Dopamine Receptor D2 Variants Exhibit Functional Consequences Depending on Different Heterotrimeric G-Protein Subunit Combinations DOI 10.3390/biomedicines13010046 Type Journal Article Author Niebrügge N Journal Biomedicines Pages 46 Link Publication